Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F mutation and endogenous erythroid colony formation in patients with polycythaemia vera.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology - 1 Jan 2000

Strnad Milica, Todoric Zivanovic Biljana, Tatomirovic Zeljka, Tarabar Olivera, Elez Marija, Radic Olga, Stamatovic Dragana

Abstract excerpt

PURPOSE: The purpose of this study was to investigate the frequency of JAK2V617F gene mutation in patients with polycythemia vera (PV) and to compare the results with the presence of endogenous erythroid colony (EEC) formation. METHODS: Peripheral blood and bone marrow samples of 28 patients with PV were analyzed. The diagnosis of PV was established according to the bone marrow criteria of the World Health...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Erythroid Precursor Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoietin

Share to EPO gene

Share to JAK2 gene

Share to Mutation

Share to Polycythemia Vera

Share to World Health Organization

Source

Identifiers

PMID: 25536606

Genes

EPO
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F mutation and endogenous erythroid colony formation in patients with polycythaemia vera.PMID 25536606Read ↗

JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.Semantic proximity Read ↗

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.Semantic proximity Read ↗

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaSemantic proximity Read ↗

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraSemantic proximity Read ↗

[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].Semantic proximity Read ↗

[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].Semantic proximity Read ↗

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.Semantic proximity Read ↗

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.Semantic proximity Read ↗

The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.